Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves

Vaccine

Volumn 31, Issue 43, 2013, Pages 4988-4994

  Morrill, John C ^a   Laughlin, Richard C ^b   Lokugamage, Nandadeva ^a   Wu, Jing ^b   Pugh, Roberta ^b   Kanani, Pooja ^b   Adams, L Garry ^b   Makino, Shinji ^a   Peters, C J ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

ArMP 12 NSm21 384; Calves; Rift Valley fever; RVF MP 12 NSm deletion vaccine

Indexed keywords

LIVE VACCINE; MP 12 NSM VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BOS TAURUS; DRUG SAFETY; GENE DELETION; IMMUNE RESPONSE; IMMUNOGENICITY; LIVESTOCK; NONHUMAN; PRIORITY JOURNAL; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; VACCINATION; VIRUS NEUTRALIZATION;

ARMP-12ΔNSM21/384; CALVES; RIFT VALLEY FEVER; RVF MP-12-NSM DELETION VACCINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CATTLE; CATTLE DISEASES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SEQUENCE DELETION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL PLAQUE ASSAY; VIRAL VACCINES;

EID: 84885184339     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.003     Document Type: Article

References (28)

1. Hightower A., Kinkade C., Nguku P.M., Anyangu A., Mutonga D., et al. Relationship of climate, geography, and geology to the incidence of Rift Valley fever in Kenya during the 2006-2007 outbreak. Am J Trop Med Hyg 2012, 86:373-380.
2. Anyamba A., Linthicum K.J., Small J., Britch S.C., Pak E., et al. Prediction, assessment of the Rift Valley fever activity in East and Southern Africa 2006-2008 and possible vector control strategies. Am J Trop Med Hyg 2010, 83:43-51.
3. Dar O., McIntyre S., Hogarth S., Heymann D. Rift Valley fever and a new paradigm of research and development for zoonotic disease control. Emerg Infect Dis 2013, 19:189-193. 10.3201/eid1902.120941.
4. Bird B.H., Nichol S.T. Breaking the chain: Rift Valley fever virus control via livestock vaccination. Curr Opin Virol 2012, 2(June (3)):315-323. 10.1016/j.coviro.2012.02.017.
5. Bird B.H., Ksiazek T.G., Nichol S.T., MacLachlan N.J. Rift Valley fever virus. J Am Vet Med Assoc 2009, 234(7):883-893.
6. von Teichman B., Engelbrecht A., Zulu G., Gungu B., Pardini A., Bouloy M. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 2011, 29:5771-5777.
7. Bird B.H., Albarino C.G., Hartman A.L., Erickson B.R., Ksiazek T.G., Nichol S.T. Rift Valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 2008, 82:2681-2691. 10.1128/JVI. 02501-07.
8. Bird B.H., Maartens L.H., Campbell S., Erasmus B.J., Erickson B.R., Dodd K.A., et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J Virol 2011, 85(24):12901-12909.
9. Bettinger G.E., Morrill J.C., Lokugamage N., Pittman P., Peters C.J. Rift Valley fever MP-12 vaccine: a university, government & industry collaborative development. IBC Life Sciences conference 17-18 July 2008, National Harbor, Baltimore, MD.
10. Morrill J.C., Jennings G.B., Caplen H., Turell M.J., Johnson A.J., et al. Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res 1987, 48:1042-1047.
11. Morrill J.C., Carpenter L., Taylor D., Ramsburg H.H., Quance J., Peters C.J. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 1991, 9(1):35-41.
12. Morrill J.C., Mebus C.A., Peters C.J. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 1997, 58(10):1104-1109.
13. Morrill J.C., Mebus C.A., Peters C.J. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 1997, 58(10):1110-1114.
14. Lokugamage N., Freiberg A.N., Morrill J.C., Ikegami T. Genetic subpopulations of rift valley fever ZH548, MP-12 and recombinant MP-12 strains. J Virol 2012, 86:13566-13575.
15. Ikegami T., Won S., Peters C.J., Makino S. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol 2006 Mar, 80(6):2933-2940.
16. Ikegami T., Makino S The pathogenesis of Rift Valley fever. Viruses 2011, 3:493-519.
17. Bishop D.H., Calisher C.H., Casals J., Chumakov M.P., Gaidamovich S.Y., et al. Bunyaviridae. Intervirology 1980, 14:125-143.
18. Walter C.T., Barr J.N. Recent advances in the molecular and cellular biology of bunyaviruses. J Gen Virol 2011, 92:2467-2484.
19. Won S., Ikegami T., Peters C.J., Makino S. NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture. J Virol 2006, 80:8274-8278.
20. Caplen H., Peters C.J., Bishop D.H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 1985, 66:2271-2277.
21. Morrill J.C., Laughlin R.C., Lokugamage N., Pugh R., Sbrana E., Weise W.J., et al. Safety and Immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine 2013, 31:559-565.
22. Won S., Ikegami T., Peters C.J., Makino S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol 2007, 81:13335-13345.
23. Meegan J.M., Yedloutschnig R.J., Peleg B.A., et al. Enzyme-linked immunosorbent assay for detection of antibodies to Rift Valley fever virus in ovine and bovine sera. Am J Vet Res 1987, 48(7):1138-1141.
24. Ksiazek T.G., Jouan A., Meegan J.M., et al. Rift Valley fever among domestic animals in the recent West African outbreak. Res Virol 1989, 140(1):67-77.
25. Yedloutschnig R.J., Dardiri A.H., Walker J.S., Peters C.J., Eddy G.A. Immune response of steers, goats and sheep to inactivated Rift Valley fever vaccine. Proc US Animal Health Assoc Ann Meet 1979, 83:253-260.
26. Harrington D.G., Lupton H.W., Crabbs C.L., et al. Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep. Am J Vet Res 1980, 41:1559-1564.
27. Turell M.J., Gargan T.P., Bailey C.L. Replication and dissemination of Rift Valley fever virus in Culex pipiens. Am J Trop Med Hyg 1984, 33:176-181.
28. Lee S.W., Markham P.F., Coppo M.J., Legione A.R., Markham J.F., Noormohammadi A.H., et al. Attenuated vaccines can recombine to form virulent field viruses. Science 2012, 337(July 6091):188. 10.1126/science.1217134.